Biotech | October 01, 2021
Jubilant concludes pre-IND meeting of JB1-802 with U.S. FDA
The company plans to submit the IND application by the end of 2021
The company plans to submit the IND application by the end of 2021
This one-of-a-kind innovation challenge is aimed at addressing the challenges faced by healthcare providers in digital technology adoption
India’s first gender-neutral HPV vaccine to help reduce HPV -related disease burden in Indian girls, women and boys
This project will be conducted at the “NURA,” a health screening centre that Fujifilm opened in India in February this year
CuraTeQ Biologics is on track for filing a second oncology biosimilar
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
Surufatinib is the third potential new medicine discovered by the company to enter into clinical development in Japan
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
_256_384.jpg)
The council has also reduced the GST to 5 per cent on a few more Covid-19 medicines
If approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC
Subscribe To Our Newsletter & Stay Updated
